LULU has entered the post-earnings week in a contradictory state: short sellers are adding at the fastest pace in months while options traders are positioned for a bounce, creating one of the more unusual setups the stock has seen this cycle.
The short-side rebuild is the clearest development since the June 4 earnings drop. Short interest has risen to 6.9% of free float — up 21% on the week and 42% over the past month. That compares with 5.8% heading into the print, which was itself flagged as a 30-day high in prior notes. Short sellers were building before the results and have not stopped since: the stock fell 9.4% on June 4 following a Q1 report that showed 700 basis points of margin erosion and a guidance cut that now points to flat-to-down revenue for FY26. Despite all that, the borrow market remains extraordinarily loose. Availability is running at 663% of short interest — more than six shares available for every one already borrowed — and cost to borrow is a nominal 0.44%. There is no squeeze pressure and no sign the lending pool is tightening. The short build looks conviction-driven, not crowded.
Options positioning is telling a different story, and the contrast matters. The put/call ratio has dropped to 0.69 — almost three standard deviations below its 20-day average of 0.78, and the lowest reading of the past year. That is the most call-skewed the options market has been in twelve months, meaning buyers are reaching for upside rather than hedging against further losses. Into a stock that just fell 9% on earnings and is down 7.5% over the past month to $121.36, that level of call-side demand is unusual. It may reflect investors positioning for a bounce toward the revised consensus target of $136, or it may reflect speculative call-buying into next quarter's print, scheduled for June 25. Either way, short interest and options are pointing in opposite directions.
The Street absorbed the earnings miss with a wave of target cuts but no downgrades. Citigroup's Paul Lejuez cut his target from $185 to $130 on June 10, maintaining Neutral. The prior session saw UBS, Telsey, Jefferies, Piper Sandler, Bernstein, Truist, Evercore ISI, and Stifel all move in the same direction — targets reduced by 20-30% on average, ratings left unchanged. Consensus now centers on a mean target of $136, roughly 12% above the current price, but that overstates the bull case: the dominant analyst view is a cluster of Neutral and Hold ratings that suggest the Street is waiting to see evidence of stabilisation rather than paying up for it. The bear case is well-documented: gross margin under structural pressure from tariffs and higher marketing spend, a new CEO with limited forward visibility, and a guidance framework that projects EPS of $10.95-$11.15 — a number the market appears to be discounting heavily at a 10.7x trailing PE and just 2.4x book. Factor scores reinforce the caution: EPS momentum ranks in the 12th percentile over 30 days, and analyst recommendation differential sits in the 5th percentile, two of the weakest readings in the universe.
One institutional footnote is worth noting. Marshall Wace cut its holding by 1.3 million shares in the most recent quarter, a meaningful trim from a firm that typically trades with directional intent. AQR, by contrast, added 1.4 million shares in the same period. The divergence between two quantitative managers on the same name, around the same time, is a reasonable proxy for how split professional opinion currently is on the recovery thesis.
The next scheduled test is the June 25 earnings event — which appears to be a Q2 print or guidance update. With the ORTEX short score rising to 46.5 and still moving higher, the gap between options optimism and short-side scepticism is the dynamic to watch into that date.
See the live data behind this article on ORTEX.
Open LULU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
